Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
908 Devices Inc. reported first quarter and three months ended March 31, 2026 results: revenue $13.4 million, net income Net loss attributable to common stockholders was $12.0 million. Guidance raised.
- Period
- first quarter and three months ended March 31, 2026
- Revenue
- $13.4 million
- Net income
- Net loss attributable to common stockholders was $12.0 million
- Guidance
- raised
- Result
- reported results
Exact text from the filing
subscriptions. This transaction reflects our focus on disciplined growth investments as we continue to execute our transformation strategy.” Recent Highlights · Revenue of $13.4 million for the first quarter of 2026, increasing 14% year over year · Recurring revenue was $4.0 million, representing 30% of total revenues for the quarter · Gross margin was 51% and
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.95
908 Devices Inc. completed an acquisition involving Florentin Coppey, Pierre Esseiva, Matteo Delbrück, Parkview Invest AG and Matthieu Girod for headline price of $15,000,000 (closed 2026-05-04).
- Action
- acquisition
- Counterparty
- Florentin Coppey, Pierre Esseiva, Matteo Delbrück, Parkview Invest AG and Matthieu Girod
- Consideration
- headline price of $15,000,000
- Closing
- 2026-05-04
Exact text from the filing
and outstanding NIRLAB Shares in exchange for a preliminary consideration (the “Preliminary Consideration”) payable by the Company on the Closing Date with a headline price of $15,000,000 (the “Transaction”), comprised of (x) $13,000,000 in cash (the “Cash Consideration”) and (y) 293,368 shares of common stock of the Company, par value $0.001 per share (each such
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
908 Devices Inc. entered into Share Purchase Agreement with Florentin Coppey, Pierre Esseiva, Matteo Delbrück, Parkview Invest AG and Matthieu Girod valued at headline price of $15,000,000 (effective 2026-05-04).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- Florentin Coppey, Pierre Esseiva, Matteo Delbrück, Parkview Invest AG and Matthieu Girod
- Value
- headline price of $15,000,000
- Effective
- 2026-05-04
Exact text from the filing
On May 4, 2026 (the “Closing Date”), 908 Devices Inc. (the “Company”) completed its acquisition of NIRLAB SA, a corporation organized under the laws of Switzerland (“NIRLAB”), and its wholly owned subsidiary, NIRLAB Forensics Sàrl, a limited liability company organized under the laws of Switzerland (the “Subsidiary” and, together with NIRLAB, the “NIRLAB Group”), pursuant to a Share Purchase Agreement (the “Purchase Agreement”) with Florentin Coppey, Pierre Esseiva, Matteo Delbrück, Parkview Invest AG and Matthieu Girod (each a “Seller” and collectively, the “Sellers”) and NIRLAB.
View on SEC.gov